ReviewFood safety (Tokyo, Japan)2017
ESBL-producing
Review in Food safety (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 75 citations in OpenAlex.
- Epidemiology and Molecular Profiles of ESBL-ProducingMicroorganisms · 2026Article
- Association between antimicrobial use and the detection rates of carbapenem-resistant Enterobacterales: long-term surveillance results from a single centre.Infection prevention in practice · 2026Article
- The Antimicrobial Peptide C14R Is Active Against All Pathogenic Species of the ESKAPE Group.Antibiotics (Basel, Switzerland) · 2026Article
- First documented extended-spectrum β-lactamase producingAnnals of medicine and surgery (2012) · 2025Article
- Antibacterial potential of antidepressants against extended-spectrum β-lactamase-producing Escherichia coli.Folia microbiologica · 2025Article
- Draft genome of an extended-spectrum β-lactamase-producing multidrug-resistantMicrobiology resource announcements · 2025Article
- Trends and patterns of antimicrobial resistance among common pathogens isolated from adult bloodstream and urinary tract infections in public health facilities in Malawi, 2020-2024.BMC infectious diseases · 2025Article
- Molecular characterization of multidrug-resistant Escherichia coli in the Greater Accra Region, Ghana: a 'One Health' approach.One health outlook · 2025Article
- Genomic characterization of extended-spectrum β-lactamase-producingApplied and environmental microbiology · 2025Article
- Extended-Spectrum-Beta-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Oral colonization of antimicrobial-resistant bacteria in home health care participants and their association with oral and systemic status.Scientific reports · 2025Article
- A plasmid with theMicrobiology (Reading, England) · 2025Article
- Threats across boundaries: the spread of ESBL-positiveFrontiers in microbiology · 2025Review
- Article
- Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2024Article
- Genetic characterization of plasmid-mediated fluoroquinolone efflux pump QepA among ESBL-producing Escherichia coli isolates in Mexico.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Article
- Article
- Article
- Genetic relatedness of third-generation cephalosporin-resistantOne health (Amsterdam, Netherlands) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since around the 2000s,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.